Glucocorticoids	O
induced	O
down-regulation	O
of	O
glucocorticoid	B-protein
receptor	I-protein
mRNA	O
expression	O
in	O
asthma	O
.	O

Although	O
their	O
precise	O
mechanism	O
of	O
action	O
remains	O
to	O
be	O
elucidated	O
,	O
glucocorticoids	O
represent	O
the	O
most	O
effective	O
therapy	O
in	O
the	O
treatment	O
of	O
asthma	O
.	O

Interactions	O
between	O
the	O
glucocorticoid	B-protein
receptor	I-protein
and	O
the	O
AP-1	B-protein
complex	I-protein
have	O
been	O
shown	O
to	O
regulate	O
the	O
transcription	O
of	O
some	O
genes	O
,	O
including	O
glucocorticoid	B-protein
receptor	I-protein
itself	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
the	O
expression	O
of	O
mRNA	B-RNA
for	O
glucocorticoid	B-protein
receptor	I-protein
in	O
human	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
obtained	O
from	O
seven	O
unstable	O
untreated	O
asthmatic	O
patients	O
who	O
were	O
subsequently	O
treated	O
with	O
high	O
doses	O
of	O
parenteral	O
corticosteroid	O
(	O
methyl	O
prednisolone	O
120	O
mg/day	O
)	O
for	O
10	O
days	O
.	O

mRNA	B-RNA
expression	O
was	O
identified	O
after	O
RNA	O
extraction	O
using	O
RNAzol	O
and	O
analysed	O
after	O
reverse	B-protein
transcriptase	I-protein
,	O
by	O
polymerase	O
chain	O
reaction	O
using	O
a	O
semiquantitative	O
competitive	O
hybridization	O
assay	O
.	O

All	O
asthmatic	O
patients	O
showed	O
an	O
improvement	O
in	O
their	O
FEV1	O
values	O
after	O
corticosteroid	O
treatment	O
(	O
per	O
cent	O
of	O
predicted	O
value	O
68.28	O
+/-	O
4.93	O
versus	O
95.57	O
+/-	O
6.41	O
,	O
P	O
<	O
0.02	O
)	O
,	O
and	O
a	O
significant	O
decrease	O
for	O
glucocorticoid	B-protein
receptor	I-protein
mRNA	B-RNA
expression	O
(	O
P	O
<	O
0.02	O
)	O
was	O
observed	O
in	O
their	O
monocytes	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
an	O
ex	O
vivo	O
down-regulation	O
for	O
the	O
glucocorticoid	B-protein
receptor	I-protein
mRNA	B-RNA
expression	O
,	O
following	O
corticosteroid	O
treatment	O
.	O

Clin	NULL
Exp	NULL
Immunol	NULL
1996	NULL
;	NULL
103:311-315	NULL
Glucocorticoids	NULL
induced	NULL
down-regulation	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
mRNA	NULL
expression	NULL
in	NULL
asthma	NULL
I.	NULL
VACHIER	NULL
,	NULL
S.	NULL
ROUX*	NULL
,	NULL
P.	NULL
CHANEZ	NULL
,	NULL
J.	NULL
LOUBATIERE*	NULL
,	NULL
B.	NULL
TEROUANNE*	NULL
,	NULL
J.	NULL
C.	NULL
NICOLAS*	NULL
&	NULL
P.	NULL
GODARD	NULL
Clinique	NULL
des	NULL
Maladies	NULL
Respiratories	NULL
,	NULL
CJF	NULL
INSERM	NULL
9210	NULL
,	NULL
Hopital	NULL
Arnaud	NULL
de	NULL
Villeneuve	NULL
,	NULL
and	NULL
*INSERM	NULL
Unité	NULL
58	NULL
,	NULL
Montpellier	NULL
,	NULL
France	NULL
(	NULL
Accepted	NULL
for	NULL
publication	NULL
26	NULL
October	NULL
1995	NULL
)	NULL
SUMMARY	NULL
Although	NULL
their	NULL
precise	NULL
mechanism	NULL
of	NULL
action	NULL
remains	NULL
to	NULL
be	NULL
elucidated	NULL
,	NULL
glucocorticoids	NULL
represent	NULL
the	NULL
most	NULL
effective	NULL
therapy	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
asthma	NULL
.	NULL

Interactions	NULL
between	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
and	NULL
the	NULL
AP-1	NULL
complex	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
regulate	NULL
the	NULL
transcription	NULL
of	NULL
some	NULL
genes	NULL
,	NULL
including	NULL
glucocorticoid	NULL
receptor	NULL
itself	NULL
.	NULL

The	NULL
aim	NULL
of	NULL
the	NULL
present	NULL
study	NULL
was	NULL
to	NULL
compare	NULL
the	NULL
expression	NULL
of	NULL
mRNA	NULL
for	NULL
glucocorticoid	NULL
receptor	NULL
in	NULL
human	NULL
blood	NULL
monocytes	NULL
obtained	NULL
from	NULL
seven	NULL
unstable	NULL
untreated	NULL
asthmatic	NULL
patients	NULL
who	NULL
were	NULL
subsequently	NULL
treated	NULL
with	NULL
high	NULL
doses	NULL
of	NULL
parenteral	NULL
corticosteroid	NULL
(	NULL
methyl	NULL
prednisolone	NULL
120	NULL
mg/	NULL
day	NULL
)	NULL
for	NULL
10	NULL
days	NULL
.	NULL

mRNA	NULL
expression	NULL
was	NULL
identified	NULL
after	NULL
RNA	NULL
extraction	NULL
using	NULL
RNAzo	NULL
!	NULL

l	NULL
and	NULL
analysed	NULL
after	NULL
reverse	NULL
transcriptase	NULL
,	NULL
by	NULL
polymerase	NULL
chain	NULL
reaction	NULL
using	NULL
a	NULL
semiquantitative	NULL
competitive	NULL
hybridization	NULL
assay	NULL
.	NULL

All	NULL
asthmatic	NULL
patients	NULL
showed	NULL
an	NULL
improvement	NULL
in	NULL
their	NULL
FEV	NULL
;	NULL
values	NULL
after	NULL
corticosteroid	NULL
treatment	NULL
(	NULL
per	NULL
cent	NULL
of	NULL
predicted	NULL
value	NULL
68-28	NULL
£493	NULL
versus	NULL
95-57	NULL
+	NULL
6-41	NULL
,	NULL
P	NULL
<	NULL
0-02	NULL
)	NULL
,	NULL
and	NULL
a	NULL
significant	NULL
decrease	NULL
for	NULL
glucocorticoid	NULL
receptor	NULL
mRNA	NULL
expression	NULL
(	NULL
P	NULL
<	NULL
0:02	NULL
)	NULL
was	NULL
observed	NULL
in	NULL
their	NULL
monocytes	NULL
.	NULL

This	NULL
is	NULL
the	NULL
first	NULL
report	NULL
of	NULL
an	NULL
ex	NULL
vivo	NULL
down-regulation	NULL
for	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
mRNA	NULL
expression	NULL
,	NULL
following	NULL
corticosteroid	NULL
treatment	NULL
.	NULL

Keywords	NULL
-	NULL
asthma	NULL
-	NULL
glucocorticoid	NULL
receptor	NULL
INTRODUCTION	NULL
Both	NULL
systemic	NULL
and	NULL
inhaled	NULL
corticosteroids	NULL
are	NULL
widely	NULL
used	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
asthma	NULL
,	NULL
but	NULL
their	NULL
underlying	NULL
mechanisms	NULL
of	NULL
action	NULL
are	NULL
still	NULL
unclear	NULL
despite	NULL
important	NULL
advances	NULL
in	NULL
understanding	NULL
their	NULL
molecular	NULL
mechanism	NULL
of	NULL
regulation	NULL
[	NULL
1	NULL
]	NULL
.	NULL

Several	NULL
studies	NULL
have	NULL
shown	NULL
a	NULL
decrease	NULL
of	NULL
cellular	NULL
infiltration	NULL
into	NULL
asthmatic	NULL
airways	NULL
following	NULL
treatment	NULL
with	NULL
glucocorticoids	NULL
(	NULL
GC	NULL
)	NULL
[	NULL
2	NULL
]	NULL
.	NULL

Generally	NULL
,	NULL
GC	NULL
are	NULL
able	NULL
to	NULL
interfere	NULL
with	NULL
the	NULL
in	NULL
vivo	NULL
production	NULL
of	NULL
inflammatory	NULL
mediators	NULL
to	NULL
suppress	NULL
the	NULL
putative	NULL
in	NULL
vivo	NULL
inflammatory	NULL
response	NULL
[	NULL
3	NULL
]	NULL
.	NULL

At	NULL
the	NULL
molecular	NULL
level	NULL
,	NULL
GC	NULL
act	NULL
by	NULL
their	NULL
binding	NULL
to	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
GR	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
dexamethasone	NULL
induced	NULL
a	NULL
down-regulation	NULL
of	NULL
GR	NULL
mRNA	NULL
and	NULL
GR	NULL
protein	NULL
in	NULL
rat	NULL
liver	NULL
or	NULL
in	NULL
human	NULL
cell	NULL
lines	NULL
[	NULL
4,5	NULL
]	NULL
.	NULL

To	NULL
our	NULL
knowledge	NULL
there	NULL
are	NULL
no	NULL
published	NULL
studies	NULL
investigating	NULL
the	NULL
regulation	NULL
of	NULL
GR	NULL
expression	NULL
ex	NULL
vivo	NULL
in	NULL
asthmatic	NULL
patients	NULL
treated	NULL
by	NULL
GC	NULL
.	NULL

Bronchial	NULL
inflammation	NULL
in	NULL
asthma	NULL
is	NULL
characterized	NULL
by	NULL
sub-mucosal	NULL
cellular	NULL
infiltration	NULL
which	NULL
appears	NULL
to	NULL
involve	NULL
cells	NULL
of	NULL
the	NULL
monocyte	NULL
lineage	NULL
[	NULL
6	NULL
]	NULL
.	NULL

There	NULL
is	NULL
some	NULL
evidence	NULL
that	NULL
circulating	NULL
blood	NULL
monocytes	NULL
are	NULL
activated	NULL
in	NULL
asthma	NULL
[	NULL
7	NULL
]	NULL
.	NULL

Monocytes	NULL
obtained	NULL
from	NULL
Correspondence	NULL
:	NULL
Dr	NULL
Isabelle	NULL
Vachier	NULL
,	NULL
Clinique	NULL
des	NULL
Maladies	NULL
Respir-atoires	NULL
,	NULL
CJF	NULL
INSERM	NULL
9210	NULL
,	NULL
Hopital	NULL
Arnaud	NULL
de	NULL
Villeneuve	NULL
,	NULL
555	NULL
Route	NULL
de	NULL
Ganges	NULL
,	NULL
34295	NULL
Montpellier	NULL
Cedex	NULL
5	NULL
,	NULL
France	NULL
.	NULL

©	NULL
1996	NULL
Blackwell	NULL
Science	NULL
corticosteroids	NULL
mRNA	NULL
-	NULL
human	NULL
blood	NULL
monocytes	NULL
corticoresistant	NULL
asthmatic	NULL
patients	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
differ	NULL
from	NULL
those	NULL
of	NULL
corticosensitive	NULL
patients	NULL
[	NULL
8	NULL
]	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
their	NULL
different	NULL
ability	NULL
to	NULL
bind	NULL
GR	NULL
to	NULL
the	NULL
glucocorticoid	NULL
responsive	NULL
element	NULL
(	NULL
GRE	NULL
)	NULL
on	NULL
DNA	NULL
[	NULL
9	NULL
]	NULL
.	NULL

On	NULL
the	NULL
contrary	NULL
,	NULL
recent	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
alteration	NULL
of	NULL
the	NULL
GR	NULL
binding	NULL
with	NULL
GC	NULL
and	NULL
GR	NULL
number	NULL
was	NULL
related	NULL
to	NULL
lymphocytes	NULL
rather	NULL
than	NULL
to	NULL
monocytes	NULL
[	NULL
10	NULL
]	NULL
.	NULL

Blood	NULL
monocytes	NULL
appear	NULL
to	NULL
be	NULL
suitable	NULL
cells	NULL
in	NULL
asthma	NULL
to	NULL
examine	NULL
the	NULL
regulation	NULL
of	NULL
GR	NULL
expression	NULL
.	NULL

The	NULL
aim	NULL
of	NULL
the	NULL
present	NULL
study	NULL
was	NULL
to	NULL
analyse	NULL
the	NULL
regulation	NULL
of	NULL
GR	NULL
mRNA	NULL
expression	NULL
in	NULL
human	NULL
blood	NULL
monocytes	NULL
from	NULL
healthy	NULL
subjects	NULL
and	NULL
asthmatic	NULL
patients	NULL
before	NULL
and	NULL
after	NULL
methylprednisolone	NULL
injection	NULL
(	NULL
120	NULL
mg/day	NULL
)	NULL
for	NULL
10	NULL
days	NULL
.	NULL

Our	NULL
findings	NULL
confirm	NULL
a	NULL
down-regulation	NULL
of	NULL
GR	NULL
[	NULL
11	NULL
]	NULL
and	NULL
extend	NULL
these	NULL
observations	NULL
ex	NULL
vivo	NULL
in	NULL
blood	NULL
monocytes	NULL
from	NULL
asthmatic	NULL
patients	NULL
.	NULL

PATIENTS	NULL
AND	NULL
METHODS	NULL
Patients	NULL
Seven	NULL
non-smoking	NULL
patients	NULL
suffering	NULL
from	NULL
unstable	NULL
asthma	NULL
with	NULL
ages	NULL
ranging	NULL
from	NULL
28	NULL
to	NULL
66	NULL
years	NULL
(	NULL
48	NULL
+4	NULL
years	NULL
(	NULL
mean	NULL
+	NULL
s.e.m	NULL
.	NULL
)	NULL

)	NULL
were	NULL
included	NULL
in	NULL
the	NULL
study	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Asthma	NULL
was	NULL
defined	NULL
according	NULL
to	NULL
the	NULL
American	NULL
Thoracic	NULL
Society	NULL
criteria	NULL
[	NULL
12	NULL
]	NULL
.	NULL

Asthma	NULL
instability	NULL
was	NULL
defined	NULL
according	NULL
to	NULL
the	NULL
presence	NULL
of	NULL
nocturnal	NULL
311	NULL
312	NULL
Table	NULL
1	NULL
.	NULL

Individual	NULL
characteristics	NULL
of	NULL
asthmatic	NULL
patients	NULL
I.	NULL
Vachier	NULL
et	NULL
al	NULL
.	NULL

FEV	NULL
;	NULL
Before	NULL
After	NULL
AFEV	NULL
;	NULL
Age	NULL
Aas	NULL
Atopy	NULL
To	NULL
No	NULL
.	NULL

Sex	NULL
(	NULL
years	NULL
)	NULL
score	NULL
(	NULL
yes/no	NULL
)	NULL
(	NULL
%	NULL
)	NULL
(	NULL
ml	NULL
)	NULL
(	NULL
%	NULL
)	NULL
(	NULL
ml	NULL
)	NULL
(	NULL
%	NULL
)	NULL
(	NULL
ml	NULL
)	NULL
1	NULL
M	NULL
28	NULL
2	NULL
Yes	NULL
72	NULL
3210	NULL
95	NULL
4160	NULL
23	NULL
950	NULL
2	NULL
M	NULL
54	NULL
2	NULL
Yes	NULL
88	NULL
3320	NULL
106	NULL
3990	NULL
18	NULL
670	NULL
3	NULL
F	NULL
66	NULL
2	NULL
No	NULL
70	NULL
1600	NULL
104	NULL
2360	NULL
34	NULL
760	NULL
4	NULL
F	NULL
47	NULL
3	NULL
Yes	NULL
60	NULL
1510	NULL
94	NULL
2400	NULL
34	NULL
882	NULL
5	NULL
M	NULL
56	NULL
3	NULL
Yes	NULL
77	NULL
2720	NULL
92	NULL
3240	NULL
15	NULL
520	NULL
6	NULL
F	NULL
39	NULL
3	NULL
No	NULL
64	NULL
1680	NULL
92	NULL
2400	NULL
28	NULL
720	NULL
7	NULL
F	NULL
30	NULL
4	NULL
Yes	NULL
47	NULL
1580	NULL
64	NULL
2080	NULL
17	NULL
500	NULL
symptoms	NULL
as	NULL
previously	NULL
described	NULL
[	NULL
7	NULL
]	NULL
,	NULL
and	NULL
severity	NULL
was	NULL
determined	NULL
according	NULL
to	NULL
the	NULL
clinical	NULL
sore	NULL
of	NULL
Aas	NULL
[	NULL
13	NULL
]	NULL
.	NULL

All	NULL
patients	NULL
had	NULL
the	NULL
same	NULL
clinical	NULL
evaluation	NULL
,	NULL
including	NULL
pulmonary	NULL
function	NULL
tests	NULL
,	NULL
allergy	NULL
skin	NULL
prick	NULL
tests	NULL
,	NULL
lung	NULL
and	NULL
sinus	NULL
x-rays	NULL
.	NULL

None	NULL
of	NULL
them	NULL
had	NULL
been	NULL
treated	NULL
by	NULL
either	NULL
inhaled	NULL
or	NULL
oral	NULL
GC	NULL
for	NULL
the	NULL
past	NULL
3	NULL
months	NULL
.	NULL

3	NULL
;	NULL
-agonists	NULL
were	NULL
used	NULL
as	NULL
needed	NULL
by	NULL
the	NULL
asthma	NULL
symptoms	NULL
.	NULL

Six	NULL
healthy	NULL
volunteers	NULL
were	NULL
also	NULL
included	NULL
in	NULL
this	NULL
study	NULL
;	NULL
they	NULL
were	NULL
age-	NULL
(	NULL
25-45	NULL
years	NULL
(	NULL
35	NULL
+5	NULL
years	NULL
)	NULL
)	NULL
and	NULL
sex-	NULL
(	NULL
3M/3F	NULL
)	NULL
matched	NULL
.	NULL

The	NULL
study	NULL
was	NULL
performed	NULL
after	NULL
informed	NULL
consent	NULL
,	NULL
and	NULL
fulfilled	NULL
the	NULL
criteria	NULL
of	NULL
the	NULL
Ethics	NULL
Committee	NULL
of	NULL
the	NULL
University	NULL
of	NULL
Montpellier	NULL
.	NULL

Monocyte	NULL
preparation	NULL
Peripheral	NULL
blood	NULL
was	NULL
recovered	NULL
by	NULL
venipuncture	NULL
at	NULL
8	NULL
am	NULL
in	NULL
heparinized	NULL
tubes	NULL
(	NULL
25	NULL
U/ml	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
isolated	NULL
by	NULL
centrifugation	NULL
of	NULL
blood	NULL
samples	NULL
overlayered	NULL
onto	NULL
isotonic	NULL
Percoll	NULL
(	NULL
Pharmacia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
solutions	NULL
as	NULL
previously	NULL
described	NULL
[	NULL
14	NULL
]	NULL
.	NULL

Briefly	NULL
,	NULL
the	NULL
mononuclear	NULL
cell	NULL
suspension	NULL
was	NULL
removed	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
contaminating	NULL
erythrocytes	NULL
were	NULL
lysed	NULL
.	NULL

After	NULL
washing	NULL
,	NULL
monocytes	NULL
were	NULL
counted	NULL
in	NULL
the	NULL
initial	NULL
cell	NULL
suspension	NULL
using	NULL
neutral	NULL
red	NULL
stain	NULL
which	NULL
allows	NULL
easy	NULL
identification	NULL
of	NULL
blood	NULL
monocytes	NULL
[	NULL
15	NULL
]	NULL
(	NULL
neutral	NULL
red/monocyte	NULL
suspension	NULL
:	NULL
3/1	NULL
)	NULL
.	NULL

Neutral	NULL
red	NULL
positive	NULL
cells	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
per	NULL
Petri	NULL
dish	NULL
)	NULL
were	NULL
then	NULL
incubated	NULL
with	NULL
2	NULL
ml	NULL
of	NULL
RPMI	NULL
1640	NULL
medium	NULL
with	NULL
20	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
;	NULL
Greco	NULL
Chemical	NULL
,	NULL
Paisley	NULL
,	NULL
UK	NULL
)	NULL
for	NULL
2	NULL
h	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
humid	NULL
atmosphere	NULL
of	NULL
95	NULL
%	NULL
air	NULL
and	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
.	NULL

The	NULL
monolayer	NULL
was	NULL
then	NULL
washed	NULL
to	NULL
remove	NULL
non-aderent	NULL
cells	NULL
.	NULL

Monocytes	NULL
were	NULL
then	NULL
frozen	NULL
directly	NULL
at	NULL
-80°C	NULL
to	NULL
protect	NULL
them	NULL
from	NULL
RNAse	NULL
attack	NULL
until	NULL
use	NULL
.	NULL

The	NULL
purity	NULL
of	NULL
monocytes	NULL
was	NULL
>	NULL
95	NULL
%	NULL
as	NULL
assessed	NULL
by	NULL
May-Griinwald	NULL
staining	NULL
.	NULL

Isolation	NULL
and	NULL
analysis	NULL
of	NULL
total	NULL
RNA	NULL
Total	NULL
cellular	NULL
RNA	NULL
was	NULL
obtained	NULL
by	NULL
lysing	NULL
cells	NULL
directly	NULL
on	NULL
the	NULL
monolayer	NULL
in	NULL
RNAzol	NULL
(	NULL
Bioprobe	NULL
System	NULL
,	NULL
Montreuil	NULL
,	NULL
France	NULL
)	NULL
following	NULL
the	NULL
manufacturer	NULL
's	NULL
protocol	NULL
according	NULL
to	NULL
a	NULL
method	NULL
derived	NULL
from	NULL
Chomcynski	NULL
&	NULL
Sacci	NULL
[	NULL
16	NULL
]	NULL
.	NULL

Briefly	NULL
,	NULL
the	NULL
extracted	NULL
RNA	NULL
in	NULL
the	NULL
aqueous	NULL
phase	NULL
was	NULL
obtained	NULL
after	NULL
homogenization	NULL
of	NULL
the	NULL
cells	NULL
in	NULL
the	NULL
reaction	NULL
mixture	NULL
containing	NULL
RNAzol	NULL
and	NULL
chloroform	NULL
(	NULL
Prolabo	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
and	NULL
after	NULL
centrifugation	NULL
at	NULL
12	NULL
000g	NULL
for	NULL
15min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
RNA	NULL
solution	NULL
extract	NULL
was	NULL
allowed	NULL
to	NULL
precipitate	NULL
with	NULL
1	NULL
v	NULL
isopropanol	NULL
at	NULL
4°C	NULL
for	NULL
15	NULL
min	NULL
and	NULL
centrifuged	NULL
at	NULL
12000	NULL
g	NULL
for	NULL
15	NULL
min	NULL
at	NULL
4°C	NULL
to	NULL
form	NULL
a	NULL
pellet	NULL
.	NULL

The	NULL
pellet	NULL
of	NULL
RNA	NULL
was	NULL
washed	NULL
with	NULL
70	NULL
%	NULL
ethanol	NULL
solution	NULL
and	NULL
vacuum	NULL
dried	NULL
briefly	NULL
,	NULL
and	NULL
was	NULL
then	NULL
solubilized	NULL
in	NULL
30	NULL
pl	NULL
H	NULL
,	NULL
O	NULL
and	NULL
stored	NULL
at	NULL
-80°C	NULL
until	NULL
subsequent	NULL
analysis	NULL
.	NULL

The	NULL
quantity	NULL
of	NULL
RNA	NULL
was	NULL
calculated	NULL
by	NULL
OD	NULL
260	NULL
spectrophotometry	NULL
.	NULL

The	NULL
integrity	NULL
of	NULL
the	NULL
purified	NULL
RNA	NULL
was	NULL
determined	NULL
by	NULL
visualization	NULL
of	NULL
the	NULL
288	NULL
and	NULL
188	NULL
ribosomal	NULL
RNA	NULL
bands	NULL
after	NULL
electrophor-esis	NULL
of	NULL
1-2	NULL
ug	NULL
of	NULL
each	NULL
RNA	NULL
sample	NULL
through	NULL
a	NULL
1	NULL
%	NULL
agaroseformaldehyde	NULL
gel	NULL
.	NULL

Reverse-transcriptase	NULL
and	NULL
polymerase	NULL
chain	NULL
reaction	NULL
Total	NULL
RNA	NULL
samples	NULL
of	NULL
02-04	NULL
pug	NULL
were	NULL
subjected	NULL
to	NULL
reverse	NULL
transcription	NULL
(	NULL
RT	NULL
)	NULL
with	NULL
oligo	NULL
dT	NULL
used	NULL
as	NULL
a	NULL
template	NULL
primer	NULL
.	NULL

First-strand	NULL
synthesis	NULL
was	NULL
carried	NULL
out	NULL
for	NULL
1h	NULL
at	NULL
37°C	NULL
in	NULL
25	NULL
pul	NULL
of	NULL
a	NULL
reaction	NULL
mixture	NULL
using	NULL
200	NULL
U	NULL
Moloney	NULL
Murine	NULL
Leukaemia	NULL
Virus	NULL
Reverse	NULL
Transcriptase	NULL
(	NULL
M-MLV	NULL
RT	NULL
;	NULL
Gisco	NULL
BRL	NULL
)	NULL
in	NULL
1	NULL
x	NULL
RT	NULL
buffer	NULL
,	NULL
05	NULL
mm	NULL
dATP	NULL
,	NULL
dGTP	NULL
,	NULL
dCTP	NULL
,	NULL
dTTP	NULL
,	NULL
10	NULL
mm	NULL
DTT	NULL
,	NULL
20	NULL
U	NULL
of	NULL
RNasin	NULL
ribonuclease	NULL
inhibitor	NULL
(	NULL
Promega	NULL
France	NULL
,	NULL
Lyon	NULL
,	NULL
France	NULL
)	NULL
and	NULL
0-25	NULL
ug	NULL
of	NULL
oligo	NULL
dT	NULL
(	NULL
Biolabs	NULL
,	NULL
Gaitherburg	NULL
,	NULL
MD	NULL
)	NULL
[	NULL
17,18	NULL
]	NULL
.	NULL

The	NULL
reaction	NULL
mixture	NULL
was	NULL
heated	NULL
to	NULL
98°C	NULL
for	NULL
5	NULL
min	NULL
to	NULL
inactivate	NULL
RT	NULL
.	NULL

Primers	NULL
for	NULL
polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
PCR	NULL
)	NULL
were	NULL
prepared	NULL
for	NULL
both	NULL
genes	NULL
:	NULL
glyceraldehyde	NULL
3-phosphate	NULL
dehydrogenase	NULL
(	NULL
GAPDH	NULL
;	NULL
171	NULL
bp	NULL
)	NULL
,	NULL
GR	NULL
(	NULL
201	NULL
bp	NULL
)	NULL
.	NULL

Much	NULL
attention	NULL
had	NULL
been	NULL
given	NULL
to	NULL
their	NULL
locus	NULL
on	NULL
the	NULL
gene	NULL
to	NULL
be	NULL
used	NULL
in	NULL
the	NULL
RT-PCR	NULL
,	NULL
and	NULL
the	NULL
sequence	NULL
of	NULL
PCR	NULL
primer	NULL
is	NULL
as	NULL
follows	NULL
:	NULL
GR	NULL
sense	NULL
5	NULL
``	NULL
CAA	NULL
AAG	NULL
AGC	NULL
AGT	NULL
GGA	NULL
AGG	NULL
ACA	NULL
3	NULL
,	NULL
GR	NULL
antisense	NULL
5°	NULL
GAG	NULL
GTT	NULL
TCT	NULL
TGT	NULL
GAG	NULL
ACT	NULL
CCT	NULL
GT	NULL
3	NULL
'	NULL
;	NULL
GAPDH	NULL
sense	NULL
5	NULL
``	NULL
TCG	NULL
CCA	NULL
GCC	NULL
GAG	NULL
CCA	NULL
CAT	NULL
3	NULL
'	NULL
,	NULL
GAPDH	NULL
antisense	NULL
5°	NULL
GGA	NULL
ACA	NULL
TGT	NULL
AAA	NULL
CCA	NULL
TGT	NULL
AGT	NULL
TG	NULL
3	NULL
'	NULL
.	NULL

Absence	NULL
of	NULL
contaminants	NULL
was	NULL
checked	NULL
by	NULL
RT-PCR	NULL
assays	NULL
of	NULL
control	NULL
samples	NULL
with	NULL
no	NULL
RNA	NULL
,	NULL
no	NULL
RT	NULL
or	NULL
PCR	NULL
reaction	NULL
buffer	NULL
only	NULL
.	NULL

PCR	NULL
assays	NULL
contained	NULL
0:5	NULL
U	NULL
Taq	NULL
DNA	NULL
polymerase	NULL
,	NULL
0-5	NULL
um	NULL
of	NULL
each	NULL
oligonucleotide	NULL
primer	NULL
,	NULL
0-2	NULL
m	NULL
dNTP	NULL
,	NULL
0-25	NULL
or	NULL
2+5	NULL
pl	NULL
of	NULL
the	NULL
RT	NULL
reaction	NULL
mixture	NULL
,	NULL
50	NULL
mm	NULL
KCI	NULL
,	NULL
10	NULL
mm	NULL
,	NULL
Tris-HCl	NULL
pH9	NULL
,	NULL
0:1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
5-15	NULL
%	NULL
glycerol	NULL
,	NULL
1:5	NULL
mm	NULL
magnesium	NULL
chloride	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
50	NULL
ul	NULL
.	NULL

An	NULL
amplification	NULL
sequence	NULL
of	NULL
28	NULL
cycles	NULL
of	NULL
denaturation	NULL
at	NULL
95°C	NULL
for	NULL
1	NULL
min	NULL
,	NULL
annealing	NULL
at	NULL
53°C	NULL
for	NULL
1	NULL
min	NULL
and	NULL
extension	NULL
at	NULL
72°C	NULL
for	NULL
2	NULL
min	NULL
was	NULL
used	NULL
.	NULL

Both	NULL
sets	NULL
of	NULL
RT	NULL
reaction	NULL
mixture	NULL
were	NULL
analysed	NULL
to	NULL
check	NULL
that	NULL
PCR	NULL
products	NULL
were	NULL
obtained	NULL
during	NULL
the	NULL
exponential	NULL
phase	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
by	NULL
Roux	NULL
et	NULL
al	NULL
.	NULL

[	NULL
19	NULL
]	NULL
.	NULL

Reproducibility	NULL
of	NULL
this	NULL
experiment	NULL
was	NULL
performed	NULL
using	NULL
U937	NULL
and	NULL
W126	NULL
cell	NULL
lines	NULL
for	NULL
GR	NULL
mRNA	NULL
expression	NULL
.	NULL

The	NULL
variation	NULL
found	NULL
for	NULL
six	NULL
different	NULL
experiments	NULL
was	NULL
less	NULL
than	NULL
4	NULL
%	NULL
for	NULL
the	NULL
same	NULL
amounts	NULL
of	NULL
mRNA	NULL
.	NULL

PCR	NULL
products	NULL
were	NULL
analysed	NULL
by	NULL
electrophoresis	NULL
in	NULL
TAE	NULL
buffer	NULL
with	NULL
ethidium	NULL
bromide-stained	NULL
(	NULL
0:5	NULL
mm	NULL
)	NULL
2	NULL
%	NULL
agarose	NULL
gel	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
cDNA	NULL
using	NULL
competitive	NULL
bioluminescence	NULL
assays	NULL
PCR	NULL
products	NULL
were	NULL
quantified	NULL
using	NULL
the	NULL
method	NULL
of	NULL
unlabelled	NULL
amplified	NULL
sequence	NULL
of	NULL
Térouanne	NULL
ef	NULL
al	NULL
.	NULL

[	NULL
20,21	NULL
]	NULL
.	NULL

Double-labelled	NULL
sequences	NULL
synthesized	NULL
by	NULL
PCR	NULL
with	NULL
biotinylated	NULL
and	NULL
©	NULL
1996	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Clinical	NULL
and	NULL
Experimental	NULL
Immunology	NULL
,	NULL
103:311-315	NULL
Glucocorticoid	NULL
receptor	NULL
down-regulation	NULL
in	NULL
glucocorticoid-treated	NULL
asthmatics	NULL
313	NULL
GAPDH	NULL
%	NULL
o	NULL
a	NULL
C40	NULL
O	NULL
21	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
bp	NULL
-171	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Polymerase	NULL
chain	NULL
reaction	NULL
(	NULL
PCR	NULL
)	NULL
products	NULL
(	NULL
8	NULL
pl	NULL
)	NULL
analysis	NULL
on	NULL
a	NULL
2	NULL
%	NULL
agarose	NULL
gel	NULL
for	NULL
mRNA	NULL
levels	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
GR	NULL
)	NULL
and	NULL
glyceraldehyde	NULL
3-phosphate	NULL
dehydrogenase	NULL
(	NULL
GAPDH	NULL
)	NULL
for	NULL
healthy	NULL
subject	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
,	NULL
asthmatic	NULL
patients	NULL
before	NULL
treatment	NULL
(	NULL
lanes	NULL
2	NULL
and	NULL
4	NULL
)	NULL
,	NULL
and	NULL
asthmatic	NULL
patients	NULL
after	NULL
treatment	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
5	NULL
)	NULL
.	NULL

Electrophoresis	NULL
was	NULL
run	NULL
in	NULL
TAE	NULL
buffer	NULL
with	NULL
ethidium	NULL
bromide	NULL
.	NULL

FITC-oligonucleotide	NULL
primers	NULL
were	NULL
used	NULL
as	NULL
DNA	NULL
probes	NULL
in	NULL
known	NULL
concentrations	NULL
.	NULL

These	NULL
probes	NULL
were	NULL
denatured	NULL
and	NULL
hybridized	NULL
in	NULL
solution	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
DNA	NULL
sequences	NULL
to	NULL
be	NULL
studied	NULL
(	NULL
PCR	NULL
products	NULL
)	NULL
.	NULL

The	NULL
remaining	NULL
reformed	NULL
double-labelled	NULL
hybrid	NULL
was	NULL
bound	NULL
to	NULL
a	NULL
bioluminescent	NULL
immunosorbent	NULL
substrate	NULL
and	NULL
detected	NULL
by	NULL
a	NULL
rapid	NULL
bioluminescent	NULL
assay	NULL
using	NULL
streptavadin-G6PDH	NULL
con-jugate	NULL
.	NULL

The	NULL
quantity	NULL
of	NULL
probe	NULL
regenerated	NULL
after	NULL
denaturation	NULL
and	NULL
hybridization	NULL
decreased	NULL
with	NULL
increasing	NULL
amounts	NULL
of	NULL
PCR	NULL
products	NULL
.	NULL

Briefly	NULL
,	NULL
PCR	NULL
products	NULL
were	NULL
diluted	NULL
in	NULL
1	NULL
x	NULL
Taq	NULL
buffer	NULL
,	NULL
5	NULL
%	NULL
glycerol	NULL
and	NULL
incubated	NULL
with	NULL
20	NULL
fm	NULL
of	NULL
the	NULL
homologous	NULL
labelled	NULL
sequence	NULL
in	NULL
100	NULL
ul	NULL
of	NULL
competitive	NULL
buffer	NULL
(	NULL
0-01	NULL
m	NULL
Tris-HCl	NULL
pH9	NULL
,	NULL
0:5m	NULL
NaCl	NULL
,	NULL
10	NULL
pg/ml	NULL
denatured	NULL
sonicated	NULL
salmon	NULL
sperm	NULL
,	NULL
05	NULL
%	NULL
gelatin	NULL
)	NULL
.	NULL

The	NULL
mixture	NULL
was	NULL
incubated	NULL
for	NULL
15	NULL
min	NULL
at	NULL
99°C	NULL
,	NULL
cooled	NULL
rapidly	NULL
to	NULL
60°C	NULL
and	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
at	NULL
this	NULL
temperature	NULL
.	NULL

Samples	NULL
were	NULL
centrifuged	NULL
and	NULL
50	NULL
ul	NULL
of	NULL
the	NULL
mixture	NULL
were	NULL
added	NULL
to	NULL
lumin-ometer	NULL
vials	NULL
with	NULL
50	NULL
pul	NULL
of	NULL
streptavidin-GGPDH	NULL
and	NULL
50	NULL
ul	NULL
of	NULL
bioluminescent	NULL
adsorbent	NULL
.	NULL

Quantification	NULL
was	NULL
performed	NULL
for	NULL
each	NULL
experiment	NULL
for	NULL
GR	NULL
and	NULL
GAPDH	NULL
PCR	NULL
products	NULL
and	NULL
the	NULL
ratio	NULL
GR/GAPDH	NULL
was	NULL
calculated	NULL
.	NULL

Statistical	NULL
analysis	NULL
Statistical	NULL
analysis	NULL
was	NULL
performed	NULL
using	NULL
non-parametric	NULL
tests	NULL
.	NULL

The	NULL
Wilcoxon	NULL
W-test	NULL
was	NULL
used	NULL
for	NULL
paired	NULL
data	NULL
comparing	NULL
asthmatic	NULL
patients	NULL
before	NULL
and	NULL
after	NULL
treatment	NULL
.	NULL

RESULTS	NULL
Patients	NULL
Table	NULL
1	NULL
presents	NULL
individual	NULL
characteristics	NULL
of	NULL
the	NULL
patients	NULL
.	NULL

All	NULL
patients	NULL
were	NULL
in	NULL
an	NULL
unstable	NULL
state	NULL
of	NULL
asthma	NULL
,	NULL
and	NULL
their	NULL
Aas	NULL
score	NULL
ranged	NULL
from	NULL
2	NULL
to	NULL
4	NULL
.	NULL

The	NULL
FEV	NULL
;	NULL
values	NULL
ranged	NULL
from	NULL
47	NULL
%	NULL
to	NULL
88	NULL
%	NULL
of	NULL
their	NULL
predicted	NULL
values	NULL
before	NULL
treatment	NULL
.	NULL

These	NULL
values	NULL
significantly	NULL
increased	NULL
in	NULL
all	NULL
asthmatic	NULL
patients	NULL
included	NULL
in	NULL
our	NULL
study	NULL
after	NULL
CG	NULL
treatment	NULL
(	NULL
68-28	NULL
+	NULL
4-93	NULL
%	NULL
(	NULL
mean	NULL
+s.e.m	NULL
.	NULL
)	NULL

before	NULL
GC	NULL
treatment	NULL
versus	NULL
95-57	NULL
+	NULL
640	NULL
%	NULL
after	NULL
;	NULL
P	NULL
<	NULL
0-02	NULL
,	NULL
Wilcoxon	NULL
W-test	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

The	NULL
improvement	NULL
of	NULL
FEV	NULL
;	NULL
was	NULL
ranged	NULL
from	NULL
500	NULL
to	NULL
950	NULL
ml	NULL
after	NULL
GC	NULL
.	NULL

Monocyte	NULL
recovery	NULL
The	NULL
number	NULL
of	NULL
monocytes	NULL
,	NULL
obtained	NULL
before	NULL
adherence	NULL
,	NULL
was	NULL
not	NULL
different	NULL
between	NULL
asthmatic	NULL
patients	NULL
and	NULL
healthy	NULL
subjects	NULL
(	NULL
1-71	NULL
x	NULL
10°	NULL
cells/ml	NULL
for	NULL
asthmatics	NULL
patients	NULL
versus	NULL
208	NULL
x	NULL
10°	NULL
cells/ml	NULL
for	NULL
healthy	NULL
subjects	NULL
)	NULL
.	NULL

In	NULL
asthmatic	NULL
patients	NULL
,	NULL
the	NULL
total	NULL
number	NULL
of	NULL
monocytes	NULL
did	NULL
not	NULL
change	NULL
after	NULL
the	NULL
treatment	NULL
period	NULL
(	NULL
171	NULL
versus	NULL
2:24	NULL
x	NULL
10°	NULL
cells/ml	NULL
)	NULL
.	NULL

mRNA	NULL
expression	NULL
The	NULL
amounts	NULL
of	NULL
GR	NULL
mRNA	NULL
in	NULL
six	NULL
healthy	NULL
subjects	NULL
and	NULL
seven	NULL
asthmatic	NULL
patients	NULL
before	NULL
treatment	NULL
with	NULL
GC	NULL
were	NULL
respectively	NULL
4:67	NULL
+	NULL
1-50	NULL
versus	NULL
6-38	NULL
+	NULL
1:4	NULL
,	NULL
without	NULL
significant	NULL
difference	NULL
.	NULL

The	NULL
individual	NULL
ratios	NULL
GR/GAPDH	NULL
mRNA	NULL
for	NULL
monocytes	NULL
of	NULL
asthmatic	NULL
patients	NULL
presented	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
show	NULL
significantly	NULL
decreased	NULL
levels	NULL
of	NULL
GR	NULL
mRNA	NULL
expression	NULL
in	NULL
monocytes	NULL
for	NULL
all	NULL
patients	NULL
after	NULL
10	NULL
days	NULL
treatment	NULL
by	NULL
GC	NULL
(	NULL
P	NULL
<	NULL
0-02	NULL
)	NULL
.	NULL

However	NULL
,	NULL
there	NULL
was	NULL
no	NULL
significant	NULL
correlation	NULL
with	NULL
the	NULL
change	NULL
in	NULL
FEV	NULL
)	NULL
.	NULL

DISCUSSION	NULL
Treatment	NULL
by	NULL
systemic	NULL
corticosteroids	NULL
induced	NULL
a	NULL
decrease	NULL
of	NULL
GR	NULL
mRNA	NULL
expression	NULL
.	NULL

Asthmatic	NULL
patients	NULL
with	NULL
variable	NULL
severity	NULL
of	NULL
disease	NULL
who	NULL
presented	NULL
an	NULL
exacerbation	NULL
and	NULL
an	NULL
airflow	NULL
obstruction	NULL
were	NULL
invited	NULL
to	NULL
participate	NULL
in	NULL
this	NULL
study	NULL
.	NULL

All	NULL
required	NULL
general	NULL
treatment	NULL
with	NULL
GC	NULL
at	NULL
home	NULL
,	NULL
and	NULL
we	NULL
chose	NULL
methylprednisolone	NULL
120	NULL
mg/day	NULL
intravenously	NULL
,	NULL
to	NULL
obtain	NULL
the	NULL
best	NULL
overall	NULL
compliance	NULL
,	NULL
and	NULL
to	NULL
achieve	NULL
the	NULL
best	NULL
clinical	NULL
and	NULL
functional	NULL
results	NULL
at	NULL
the	NULL
end	NULL
of	NULL
the	NULL
treatment	NULL
period	NULL
.	NULL

All	NULL
patients	NULL
displayed	NULL
an	NULL
improvement	NULL
in	NULL
airway	NULL
obstruction	NULL
,	NULL
reaching	NULL
an	NULL
absolute	NULL
increase	NULL
of	NULL
190	NULL
ml	NULL
for	NULL
the	NULL
FEV	NULL
;	NULL
values	NULL
.	NULL

This	NULL
value	NULL
has	NULL
been	NULL
previously	NULL
described	NULL
as	NULL
the	NULL
minimal	NULL
value	NULL
defining	NULL
reversibility	NULL
[	NULL
22	NULL
]	NULL
.	NULL

By	NULL
this	NULL
criterion	NULL
,	NULL
all	NULL
patients	NULL
were	NULL
corticosteroid-sensitive	NULL
according	NULL
to	NULL
Carmichael	NULL
's	NULL
definition	NULL
[	NULL
23	NULL
]	NULL
.	NULL

The	NULL
low	NULL
amounts	NULL
of	NULL
mRNA	NULL
obtained	NULL
after	NULL
extraction	NULL
compelled	NULL
us	NULL
to	NULL
amplify	NULL
the	NULL
products	NULL
of	NULL
transcription	NULL
using	NULL
a	NULL
quantitative	NULL
PCR	NULL
method	NULL
[	NULL
24	NULL
]	NULL
.	NULL

This	NULL
method	NULL
was	NULL
established	NULL
and	NULL
validated	NULL
by	NULL
Térouanne	NULL
et	NULL
al	NULL
.	NULL

[	NULL
20,21	NULL
]	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
denaturation	NULL
and	NULL
reannealing	NULL
of	NULL
a	NULL
double-strand	NULL
DNA	NULL
sequence	NULL
in	NULL
the	NULL
presence	NULL
©	NULL
1996	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Clinical	NULL
and	NULL
Experimental	NULL
Immunology	NULL
,	NULL
103:311-315	NULL
314	NULL
I.	NULL
Vachier	NULL
et	NULL
al	NULL
.	NULL

P	NULL
<	NULL
0-02	NULL
P	NULL
<	NULL
0-02	NULL
-a	NULL
m	NULL
o	NULL
(	NULL
~	NULL
1	NULL
-	NULL
(	NULL
a	NULL
)	NULL
5	NULL
100	NULL
w	NULL
o	NULL
I	NULL
LJ	NULL
o	NULL
c	NULL
o	NULL
I	NULL
ratio	NULL
GR/GAPDH	NULL
n	NULL
@	NULL
w	NULL
6	NULL
o	NULL
I	NULL
I	NULL
GR	NULL
mRNA	NULL
expression	NULL
FEV	NULL
;	NULL
(	NULL
%	NULL
of	NULL
predicted	NULL
values	NULL
)	NULL
a	NULL
o	NULL
T	NULL
T	NULL
40	NULL
___	NULL
L	NULL
p22	NULL
ply	NULL
Before	NULL
After	NULL
After	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Effects	NULL
of	NULL
10	NULL
days	NULL
treatment	NULL
with	NULL
120	NULL
mg	NULL
prednisolone	NULL
on	NULL
each	NULL
asthmatic	NULL
patient	NULL
.	NULL

(	NULL
a	NULL
)	NULL
FEV	NULL
,	NULL
expressed	NULL
as	NULL
per	NULL
cent	NULL
of	NULL
predicted	NULL
value	NULL
before	NULL
and	NULL
after	NULL
treatment	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Glucocorticoid	NULL
receptor	NULL
(	NULL
GR	NULL
)	NULL
mRNA	NULL
level	NULL
expressed	NULL
as	NULL
the	NULL
ratio	NULL
GR/glyceraldehyde	NULL
3-phosphate	NULL
dehydrogenase	NULL
(	NULL
GAPDH	NULL
)	NULL
obtained	NULL
in	NULL
human	NULL
blood	NULL
monocytes	NULL
from	NULL
asthmatic	NULL
patients	NULL
before	NULL
and	NULL
after	NULL
treatment	NULL
.	NULL

Statistical	NULL
analysis	NULL
shows	NULL
significant	NULL
differences	NULL
using	NULL
Wilcoxon	NULL
W-test	NULL
.	NULL

Before	NULL
of	NULL
a	NULL
homologous	NULL
probe	NULL
(	NULL
double-labelled	NULL
with	NULL
biotin	NULL
and	NULL
fluores-cein	NULL
)	NULL
.	NULL

GAPDH	NULL
expression	NULL
was	NULL
always	NULL
the	NULL
same	NULL
in	NULL
all	NULL
subjects	NULL
and	NULL
was	NULL
used	NULL
as	NULL
our	NULL
internal	NULL
control	NULL
to	NULL
express	NULL
results	NULL
as	NULL
a	NULL
ratio	NULL
.	NULL

DNA	NULL
sequences	NULL
were	NULL
obtained	NULL
by	NULL
RT-PCR	NULL
after	NULL
total	NULL
RNA	NULL
extraction	NULL
using	NULL
RNAzol	NULL
kit	NULL
extract	NULL
.	NULL

No	NULL
difference	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
GR	NULL
mRNA	NULL
was	NULL
observed	NULL
between	NULL
healthy	NULL
and	NULL
asthmatic	NULL
subjects	NULL
.	NULL

This	NULL
result	NULL
shows	NULL
that	NULL
circulating	NULL
inflammatory	NULL
mediators	NULL
which	NULL
are	NULL
increased	NULL
in	NULL
asthma	NULL
did	NULL
not	NULL
modulate	NULL
the	NULL
expression	NULL
of	NULL
GR	NULL
mRNA	NULL
.	NULL

Based	NULL
upon	NULL
these	NULL
results	NULL
,	NULL
there	NULL
are	NULL
no	NULL
data	NULL
to	NULL
support	NULL
an	NULL
abnormal	NULL
expression	NULL
of	NULL
GR	NULL
mRNA	NULL
related	NULL
to	NULL
asthma	NULL
status	NULL
.	NULL

GC	NULL
are	NULL
the	NULL
most	NULL
effective	NULL
therapy	NULL
available	NULL
for	NULL
controlling	NULL
asthma	NULL
,	NULL
and	NULL
their	NULL
effects	NULL
have	NULL
been	NULL
demonstrated	NULL
at	NULL
several	NULL
levels	NULL
.	NULL

Dexamethasone	NULL
decreases	NULL
GR	NULL
mRNA	NULL
levels	NULL
by	NULL
decreasing	NULL
receptor	NULL
gene	NULL
transcription	NULL
with	NULL
an	NULL
homologous	NULL
regulation	NULL
[	NULL
25	NULL
]	NULL
,	NULL
and	NULL
other	NULL
heterologous	NULL
regulation	NULL
can	NULL
also	NULL
be	NULL
observed	NULL
.	NULL

A	NULL
marked	NULL
reduction	NULL
in	NULL
GR	NULL
mRNA	NULL
was	NULL
described	NULL
in	NULL
human	NULL
lung	NULL
tissue	NULL
after	NULL
exposure	NULL
to	NULL
steroids	NULL
in	NULL
vitro	NULL
[	NULL
26	NULL
]	NULL
.	NULL

A	NULL
decrease	NULL
of	NULL
protein	NULL
and	NULL
mRNA	NULL
expression	NULL
was	NULL
described	NULL
in	NULL
vivo	NULL
in	NULL
rat	NULL
liver	NULL
after	NULL
an	NULL
exposure	NULL
to	NULL
GC	NULL
[	NULL
4,27	NULL
]	NULL
.	NULL

All	NULL
these	NULL
studies	NULL
show	NULL
that	NULL
GR	NULL
and	NULL
its	NULL
ability	NULL
to	NULL
bind	NULL
GRE	NULL
may	NULL
be	NULL
important	NULL
factors	NULL
which	NULL
influence	NULL
the	NULL
efficacy	NULL
of	NULL
the	NULL
various	NULL
sensitivities	NULL
of	NULL
GC	NULL
treatments	NULL
.	NULL

The	NULL
down-regulation	NULL
of	NULL
GR	NULL
is	NULL
unlikely	NULL
to	NULL
be	NULL
due	NULL
to	NULL
a	NULL
decrease	NULL
in	NULL
mRNA	NULL
half-life	NULL
,	NULL
but	NULL
the	NULL
GC	NULL
regulate	NULL
GR	NULL
mRNA	NULL
levels	NULL
by	NULL
influencing	NULL
gene	NULL
transcription	NULL
[	NULL
28	NULL
]	NULL
.	NULL

This	NULL
study	NULL
shows	NULL
,	NULL
for	NULL
the	NULL
first	NULL
time	NULL
,	NULL
that	NULL
this	NULL
down-regulation	NULL
can	NULL
be	NULL
observed	NULL
ex	NULL
vivo	NULL
on	NULL
human	NULL
blood	NULL
monocytes	NULL
after	NULL
exposure	NULL
to	NULL
GC	NULL
for	NULL
10	NULL
days	NULL
.	NULL

It	NULL
was	NULL
not	NULL
possible	NULL
to	NULL
perform	NULL
this	NULL
ex	NULL
vivo	NULL
study	NULL
in	NULL
control	NULL
subjects	NULL
for	NULL
ethical	NULL
reasons	NULL
,	NULL
but	NULL
according	NULL
to	NULL
the	NULL
previous	NULL
results	NULL
using	NULL
cell	NULL
lines	NULL
and	NULL
in	NULL
vivo	NULL
studies	NULL
in	NULL
rat	NULL
liver	NULL
,	NULL
GR	NULL
mRNA	NULL
expression	NULL
may	NULL
also	NULL
be	NULL
down-regulated	NULL
in	NULL
non-asthmatic	NULL
patients	NULL
.	NULL

The	NULL
regulation	NULL
of	NULL
hormone	NULL
receptors	NULL
is	NULL
an	NULL
important	NULL
aspect	NULL
of	NULL
physiologic	NULL
control	NULL
,	NULL
since	NULL
the	NULL
sensitivity	NULL
of	NULL
cells	NULL
to	NULL
this	NULL
hormone	NULL
is	NULL
directly	NULL
related	NULL
to	NULL
receptor	NULL
concentration	NULL
,	NULL
though	NULL
the	NULL
role	NULL
of	NULL
this	NULL
physiological	NULL
regulation	NULL
is	NULL
still	NULL
unclear	NULL
.	NULL

In	NULL
fact	NULL
the	NULL
down-regulation	NULL
of	NULL
GR	NULL
MRNA	NULL
does	NULL
not	NULL
reflect	NULL
a	NULL
lower	NULL
sensitivity	NULL
of	NULL
the	NULL
GC	NULL
via	NULL
reduced	NULL
GR	NULL
function	NULL
[	NULL
29	NULL
]	NULL
.	NULL

This	NULL
down-regulation	NULL
may	NULL
be	NULL
a	NULL
protective	NULL
process	NULL
for	NULL
the	NULL
cells	NULL
,	NULL
since	NULL
GR	NULL
may	NULL
have	NULL
deleterious	NULL
effects	NULL
by	NULL
increasing	NULL
GR	NULL
mRNA	NULL
expression	NULL
with	NULL
positive	NULL
autoregulation	NULL
.	NULL

Therefore	NULL
,	NULL
down-regulation	NULL
might	NULL
occur	NULL
without	NULL
any	NULL
difference	NULL
in	NULL
the	NULL
total	NULL
protein	NULL
level	NULL
of	NULL
GR	NULL
,	NULL
but	NULL
rather	NULL
via	NULL
a	NULL
decrease	NULL
in	NULL
the	NULL
de	NULL
novo	NULL
turn-over	NULL
of	NULL
the	NULL
protein	NULL
.	NULL

This	NULL
study	NULL
demonstrates	NULL
down-regulation	NULL
of	NULL
GR	NULL
mRNA	NULL
expression	NULL
ex	NULL
vivo	NULL
in	NULL
asthmatic	NULL
patients	NULL
treated	NULL
with	NULL
GC	NULL
.	NULL

ACKNOWLEDGMENT	NULL
We	NULL
thank	NULL
Professor	NULL
Jean	NULL
Bousquet	NULL
for	NULL
his	NULL
helpful	NULL
discussions	NULL
in	NULL
preparing	NULL
the	NULL
manuscript	NULL
.	NULL

This	NULL
work	NULL
is	NULL
dedicated	NULL
to	NULL
the	NULL
memory	NULL
of	NULL
Dr	NULL
Marcelle	NULL
Damon	NULL
.	NULL

REFERENCES	NULL
s	NULL
Miesfield	NULL
RL	NULL
.	NULL

Molecular	NULL
genetics	NULL
of	NULL
corticosteroid	NULL
action	NULL
.	NULL

Am	NULL
Rev	NULL
Respir	NULL
Dis	NULL
1990	NULL
;	NULL
141:11-17	NULL
.	NULL

2	NULL
Rinehart	NULL
JJ	NULL
,	NULL
Sagone	NULL
AL	NULL
,	NULL
Balcerzack	NULL
SP	NULL
,	NULL
Ackerman	NULL
A	NULL
,	NULL
Lobuglio	NULL
AF	NULL
.	NULL

Effects	NULL
of	NULL
corticosteroid	NULL
therapy	NULL
on	NULL
human	NULL
monocyte	NULL
function	NULL
.	NULL

N	NULL
Eng	NULL
J	NULL
Med	NULL
1975	NULL
;	NULL
292:236-41	NULL
.	NULL

3	NULL
Bames	NULL
PJ	NULL
,	NULL
Adock	NULL
I.	NULL
Anti-inflammatory	NULL
actions	NULL
of	NULL
steroids	NULL
;	NULL
molecular	NULL
mechanisms	NULL
.	NULL

TIPS	NULL
1993	NULL
;	NULL
14:436-41	NULL
.	NULL

4	NULL
Okret	NULL
S	NULL
,	NULL
Dong	NULL
Y	NULL
,	NULL
Bronnegard	NULL
M	NULL
,	NULL
Gustafsson	NULL
JA	NULL
.	NULL

Regulation	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
expression	NULL
.	NULL

Biochimie	NULL
1991	NULL
;	NULL
73:51-59	NULL
.	NULL

5	NULL
Silva	NULL
CM	NULL
,	NULL
Powell-Oliver	NULL
FE	NULL
,	NULL
Jewell	NULL
CM	NULL
,	NULL
Sar	NULL
M	NULL
,	NULL
Allgood	NULL
VE	NULL
,	NULL
Cidlowski	NULL
JA	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
human	NULL
glucocorticoid	NULL
receptor	NULL
by	NULL
long-term	NULL
and	NULL
chronic	NULL
treatment	NULL
with	NULL
glucocorticoid	NULL
.	NULL

Steroids	NULL
1994	NULL
;	NULL
59:436-42	NULL
.	NULL

6	NULL
Poston	NULL
RN	NULL
,	NULL
Chanez	NULL
P	NULL
,	NULL
Lacoste	NULL
JY	NULL
,	NULL
Litchfield	NULL
T	NULL
,	NULL
Lee	NULL
TH	NULL
,	NULL
Bousquet	NULL
J.	NULL
Immunohistochemical	NULL
characterization	NULL
of	NULL
the	NULL
cellular	NULL
infiltration	NULL
in	NULL
asthmatic	NULL
bronchi	NULL
.	NULL

Am	NULL
Rev	NULL
Respir	NULL
Dis	NULL
1992	NULL
;	NULL
145:918-21	NULL
.	NULL

7	NULL
Vachier	NULL
I	NULL
,	NULL
Chanez	NULL
P	NULL
,	NULL
Le	NULL
Doucen	NULL
C	NULL
,	NULL
Damon	NULL
M	NULL
,	NULL
Descomps	NULL
B	NULL
,	NULL
Godard	NULL
P.	NULL
Enhancement	NULL
of	NULL
reactive	NULL
oxygen	NULL
species	NULL
formation	NULL
in	NULL
stable	NULL
and	NULL
unstable	NULL
asthmatic	NULL
patients	NULL
.	NULL

Eur	NULL
Respir	NULL
J	NULL
1994	NULL
;	NULL
7:1585-92	NULL
.	NULL

8	NULL
Wilkinson	NULL
JR	NULL
,	NULL
Lane	NULL
SJ	NULL
,	NULL
Lee	NULL
TH	NULL
.	NULL

Effects	NULL
of	NULL
corticosteroids	NULL
on	NULL
cytokine	NULL
generation	NULL
and	NULL
expression	NULL
of	NULL
activation	NULL
antigens	NULL
by	NULL
monocytes	NULL
in	NULL
bronchial	NULL
asthma	NULL
.	NULL

Int	NULL
Arch	NULL
Allergy	NULL
Appl	NULL
Immunol	NULL
1991	NULL
;	NULL
94:220-1	NULL
.	NULL

9	NULL
Adcock	NULL
IM	NULL
,	NULL
Brown	NULL
CR	NULL
,	NULL
Peters	NULL
MJ	NULL
et	NULL
al	NULL
.	NULL

DNA	NULL
binding	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
from	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
of	NULL
steroid	NULL
sensitive	NULL
and	NULL
resistant	NULL
patients	NULL
.	NULL

Am	NULL
Rev	NULL
Respir	NULL
Dis	NULL
1993	NULL
;	NULL
147	NULL
:	NULL
A244	NULL
(	NULL
Abstr	NULL
.	NULL
)	NULL

.	NULL

10	NULL
Sher	NULL
ER	NULL
,	NULL
Leung	NULL
DYM	NULL
,	NULL
Surs	NULL
W	NULL
et	NULL
al	NULL
.	NULL

Steroid	NULL
resistant	NULL
asthma	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
1993	NULL
;	NULL
93:33-39	NULL
.	NULL

11	NULL
Burnstein	NULL
KL	NULL
,	NULL
Cidlowski	NULL
JA	NULL
.	NULL

The	NULL
down	NULL
side	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
regulation	NULL
.	NULL

Mol	NULL
Cell	NULL
Endocrinol	NULL
1992	NULL
;	NULL
83	NULL
:	NULL
C1-C8	NULL
.	NULL

12	NULL
American	NULL
Thoracic	NULL
Society	NULL
.	NULL

Standard	NULL
for	NULL
diagnosis	NULL
and	NULL
care	NULL
of	NULL
patients	NULL
with	NULL
chronic	NULL
obstructive	NULL
disease	NULL
(	NULL
COPD	NULL
)	NULL
and	NULL
asthma	NULL
.	NULL

Am	NULL
Rev	NULL
Respir	NULL
Dis	NULL
1997	NULL
;	NULL
136:225-45	NULL
.	NULL

13	NULL
Aas	NULL
K.	NULL
Heterogeneity	NULL
of	NULL
bronchial	NULL
asthma	NULL
:	NULL
subpopulation	NULL
or	NULL
different	NULL
stages	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

Allergy	NULL
1981	NULL
;	NULL
36:3-14	NULL
.	NULL

14	NULL
Vachier	NULL
I	NULL
,	NULL
Damon	NULL
M	NULL
,	NULL
Le	NULL
Doucen	NULL
C	NULL
et	NULL
al	NULL
.	NULL

Increased	NULL
oxygen	NULL
species	NULL
generation	NULL
in	NULL
blood	NULL
monocytes	NULL
of	NULL
asthmatic	NULL
patients	NULL
.	NULL

Am	NULL
Rev	NULL
Respir	NULL
Dis	NULL
1992	NULL
;	NULL
146:1161-6	NULL
.	NULL

15	NULL
Polgar	NULL
K	NULL
,	NULL
Abel	NULL
G	NULL
,	NULL
Sipka	NULL
S	NULL
,	NULL
Papp	NULL
Z.	NULL
Neutral-red	NULL
uptake	NULL
and	NULL
expression	NULL
of	NULL
monocytic	NULL
antigens	NULL
in	NULL
amniotic-fluid	NULL
mononuclear	NULL
phagocytes	NULL
.	NULL

An	NULL
J	NULL
Reprod	NULL
Immunol	NULL
Microbiol	NULL
1988	NULL
;	NULL
18:81-6	NULL
.	NULL

16	NULL
Chomezynski	NULL
P	NULL
,	NULL
Sacchi	NULL
N.	NULL
Single-step	NULL
method	NULL
of	NULL
RNA	NULL
isolation	NULL
by	NULL
acid	NULL
guanidium	NULL
thiocyanate-phenol-chloroform	NULL
extraction	NULL
.	NULL

Anal	NULL
Biochem	NULL
1987	NULL
;	NULL
162:156-9	NULL
.	NULL

17	NULL
Chelly	NULL
J	NULL
,	NULL
Kaplan	NULL
JC	NULL
,	NULL
Maire	NULL
P	NULL
,	NULL
Gautron	NULL
S	NULL
,	NULL
Khan	NULL
A	NULL
.	NULL

Transcription	NULL
of	NULL
the	NULL
dystrophin	NULL
gene	NULL
in	NULL
human	NULL
muscle	NULL
and	NULL
non-muscle	NULL
tissues	NULL
.	NULL

Nature	NULL
1988	NULL
;	NULL
333:858-60	NULL
.	NULL

18	NULL
Rappolee	NULL
DA	NULL
,	NULL
Werb	NULL
Z.	NULL
mRNA	NULL
phenotyping	NULL
to	NULL
study	NULL
gene	NULL
expression	NULL
in	NULL
small	NULL
numbers	NULL
of	NULL
cells	NULL
:	NULL
platelet-derived	NULL
growth	NULL
factor	NULL
and	NULL
other	NULL
factors	NULL
in	NULL
wound-derived	NULL
macrophages	NULL
.	NULL

Am	NULL
J	NULL
Respir	NULL
Cell	NULL
Mol	NULL
Biol	NULL
1990	NULL
;	NULL
2:3-	NULL
10	NULL
.	NULL

©	NULL
1996	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Clinical	NULL
and	NULL
Experimental	NULL
Immunology	NULL
,	NULL
103:311-315	NULL
19	NULL
20	NULL
21	NULL
22	NULL
23	NULL
24	NULL
Glucocorticoid	NULL
receptor	NULL
down-regulation	NULL
in	NULL
glucocorticoid-treated	NULL
asthmatics	NULL
Roux	NULL
S	NULL
,	NULL
Térouanne	NULL
B	NULL
,	NULL
Defacque	NULL
H	NULL
,	NULL
Vachier	NULL
I	NULL
,	NULL
Loubatiére	NULL
J	NULL
,	NULL
Nicolas	NULL
JC	NULL
.	NULL

Nonradioactive	NULL
quantification	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
expression	NULL
during	NULL
differentiation	NULL
of	NULL
human	NULL
monocytic	NULL
cells	NULL
(	NULL
U937	NULL
)	NULL
.	NULL

Anal	NULL
Biochem	NULL
1995	NULL
;	NULL
227:235-41	NULL
.	NULL

Térouanne	NULL
B	NULL
,	NULL
Balaguer	NULL
P	NULL
,	NULL
Boussioux	NULL
AM	NULL
,	NULL
Nicolas	NULL
JC	NULL
.	NULL

Quantitative	NULL
and	NULL
qualitative	NULL
analysis	NULL
of	NULL
amplified	NULL
DNA	NULL
sequences	NULL
by	NULL
a	NULL
competive	NULL
hybridization	NULL
assay	NULL
.	NULL

Anal	NULL
Biochem	NULL
1992	NULL
;	NULL
205:193-9	NULL
.	NULL

Balaguer	NULL
P	NULL
,	NULL
Térouanne	NULL
B	NULL
,	NULL
Villebrun	NULL
MA	NULL
,	NULL
Boussioux	NULL
AM	NULL
,	NULL
Nicolas	NULL
JC	NULL
.	NULL

Glucose	NULL
6-phosphate	NULL
dehydrogenase	NULL
.	NULL

Non	NULL
isotropic	NULL
DNA	NULL
probe	NULL
techniques	NULL
Kricka	NULL
LJ	NULL
,	NULL
ed	NULL
.	NULL

New	NULL
York	NULL
:	NULL
Academic	NULL
Press	NULL
,	NULL
1992	NULL
.	NULL

Reversibility	NULL
of	NULL
airflow	NULL
obstruction	NULL
:	NULL
FEV1	NULL
vs	NULL
peak	NULL
flow	NULL
.	NULL

Lancet	NULL
1992	NULL
;	NULL
340:85-86	NULL
.	NULL

Carmichael	NULL
J	NULL
,	NULL
Palerson	NULL
IC	NULL
,	NULL
Diaz	NULL
P	NULL
,	NULL
Crompton	NULL
GF	NULL
,	NULL
Kay	NULL
AB	NULL
,	NULL
Grant	NULL
IWB	NULL
.	NULL

Corticosteroid	NULL
resistance	NULL
in	NULL
chronic	NULL
asthma	NULL
.	NULL

Br	NULL
Med	NULL
J	NULL
1981	NULL
;	NULL
282:1419-22	NULL
.	NULL

Oka	NULL
T	NULL
,	NULL
Matsunaga	NULL
H	NULL
,	NULL
Tokunaga	NULL
L	NULL
,	NULL
Mitsunaga	NULL
S	NULL
,	NULL
Juji	NULL
T	NULL
,	NULL
Yamane	NULL
A	NULL
.	NULL

A	NULL
simple	NULL
method	NULL
for	NULL
detecting	NULL
single	NULL
base	NULL
substitution	NULL
and	NULL
its	NULL
application	NULL
to	NULL
HLA-DPBI1	NULL
typing	NULL
.	NULL

Nucl	NULL
Acids	NULL
Res	NULL
1994	NULL
;	NULL
22:1541-7	NULL
.	NULL

25	NULL
26	NULL
27	NULL
28	NULL
29	NULL
315	NULL
Schleimer	NULL
RP	NULL
.	NULL

Effects	NULL
of	NULL
glucocorticoids	NULL
on	NULL
inflammatory	NULL
cells	NULL
relevant	NULL
to	NULL
their	NULL
therapeutic	NULL
application	NULL
in	NULL
asthma	NULL
.	NULL

Am	NULL
Rev	NULL
Respir	NULL
Dis	NULL
1990	NULL
;	NULL
141:859-69	NULL
.	NULL

Adock	NULL
IM	NULL
,	NULL
Bronnegard	NULL
M	NULL
,	NULL
Barnes	NULL
PJ	NULL
.	NULL

Glucocorticoid	NULL
receptor	NULL
mRNA	NULL
localization	NULL
and	NULL
expression	NULL
in	NULL
human	NULL
lung	NULL
.	NULL

Am	NULL
Rev	NULL
Respir	NULL
Dis	NULL
1991	NULL
;	NULL
143	NULL
:	NULL
A628	NULL
.	NULL

Rosewicz	NULL
S	NULL
,	NULL
MacDonald	NULL
AR	NULL
,	NULL
Maddux	NULL
BA	NULL
,	NULL
Godfine	NULL
ID	NULL
,	NULL
Miesfeld	NULL
RL	NULL
,	NULL
Logsden	NULL
CD	NULL
.	NULL

Mechanism	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
down-regulation	NULL
by	NULL
glucocorticoids	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
1988	NULL
;	NULL
263:2581-4	NULL
.	NULL

Okret	NULL
S	NULL
,	NULL
Poellinger	NULL
L	NULL
,	NULL
Dong	NULL
Y	NULL
,	NULL
Gustafson	NULL
JA	NULL
.	NULL

Down-regulation	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
mRNA	NULL
by	NULL
glucocorticoid	NULL
hormones	NULL
and	NULL
recognition	NULL
by	NULL
the	NULL
receptor	NULL
of	NULL
a	NULL
specific	NULL
binding	NULL
sequence	NULL
within	NULL
a	NULL
receptor	NULL
cDNA	NULL
clone	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
1986	NULL
;	NULL
83:5899-903	NULL
.	NULL

Schlaghecke	NULL
R	NULL
,	NULL
Beuscher	NULL
D	NULL
,	NULL
Kornely	NULL
E	NULL
,	NULL
Specker	NULL
C.	NULL
Effect	NULL
of	NULL
glucocorticoid	NULL
receptors	NULL
do	NULL
not	NULL
result	NULL
in	NULL
glucocorticoid	NULL
resistance	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
1994	NULL
;	NULL
37:1127-31	NULL
.	NULL

©	NULL
1996	NULL
Blackwell	NULL
Science	NULL
Ltd	NULL
,	NULL
Clinical	NULL
and	NULL
Experimental	NULL
Immunology	NULL
,	NULL
103:311-315	NULL

